Current
Neuro-Oncology


Volume 23 Number 6
March 2021


Home > Publications > Current Neuro-Oncology > Volume 23, Year 2021 > Number 6, March



Contents


Central nervous system tumors


Gliomas


High-grade gliomas


Low-grade gliomas


Diffuse astrocytic and oligodendroglial tumors


Glioblastoma


Diffuse Midline Glioma


Embryonal tumors


Medulloblastoma


Meningiomas


Mesenchimal non-meningothelial tumors


Hemangiopericytoma


Metastatic tumors



Central nervous system tumors


Alshammari QT, Salih M, Gameraddin M, Malik BA, Yousef M, Loaz O.
Accuracy of magnetic resonance spectroscopy in discrimination of neoplastic and non-neoplastic brain lesions.
Curr Med Imaging. 2021 Feb 23. doi: 10.2174/1573405617666210224112808. Epub ahead of print. PMID: 33655843. Population-based study;




Hajtovic S, Mogilner A, Ard J, Gautreaux JE, Britton H, Fatterpekar G, Young MG, Placantonakis DG.
Awake Laser Ablation for Patients With Tumors in Eloquent Brain Areas: Operative Technique and Case Series.
Cureus. 2020 Dec 20;12(12):e12186. doi: 10.7759/cureus.12186. PMID: 33489596. Case series.



Gliomas


Franceschi E, De Biase D, Di Nunno V, Pession A, Tosoni A, Gatto L, Tallini G, Visani M, Lodi R, Bartolini S, Brandes AA.
IDH1 Non-Canonical Mutations and Survival in Patients with Glioma.
Diagnostics (Basel). 2021 Feb 19;11(2):342. doi: 10.3390/diagnostics11020342. PMID: 33669525. Retrospective analysis.




Jamshidi AM, Eichberg DG, Komotar RJ, Ivan M.
Safety Analysis of Bilateral Laser Interstitial Thermal Therapy for Treatment of Butterfly Glioma.
World Neurosurg. 2020 Dec;144:e156-e163. doi: 10.1016/j.wneu.2020.08.053. Epub 2020 Aug 11. PMID: 32795682. Retrospective analysis.




Jean-Quartier C, Jeanquartier F, Ridvan A, Kargl M, Mirza T, Stangl T, Markaĉ R, Jurada M, Holzinger A.
Mutation-based clustering and classification analysis reveals distinctive age groups and age-related biomarkers for glioma.
BMC Med Inform Decis Mak. 2021 Feb 27;21(1):77. doi: 10.1186/s12911-021-01420-1. PMID: 33639927. Laboratory investigation.




Li J, Huang W, Piao M, Liu Z, Ji S, Xue J, Zhu X.
Efficacy of bevacizumab combined with temozolomide dose-dense regimen on recurrent glioma.
J BUON. 2021 Jan-Feb;26(1):145-151. PMID: 33721445. Retrospective analysis.




Pitskhelauri D, Bykanov A, Konovalov A, Danilov G, Buklina S, Sanikidze A, Sufianov R.
Transsylvian Insular Glioma Surgery: New Classification System, Clinical Outcome in a Consecutive Series of 79 Cases.
Oper Neurosurg (Hagerstown). 2021 Mar 2:opab051. doi: 10.1093/ons/opab051. Epub ahead of print. PMID: 33677610. Retrospective abalysis;




Tatekawa H, Hagiwara A, Uetani H, Bahri S, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM.
Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET.
Cancer Imaging. 2021 Mar 10;21(1):27. doi: 10.1186/s40644-021-00396-5. PMID: 33691798. Retrospective analysis.




Yogananda CGB, Shah BR, Nalawade SS, Murugesan GK, Yu FF, Pinho MC, Wagner BC, Mickey B, Patel TR, Fei B, Madhuranthakam AJ, Maldjian JA.
MRI-Based Deep-Learning Method for Determining Glioma MGMT Promoter Methylation Status.
AJNR Am J Neuroradiol. 2021 Mar 4. doi: 10.3174/ajnr.A7029. Epub ahead of print. PMID: 33664111. Retrospective analysis.




Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, Wu F, Chai R, Wang Z, Zhang C, Zhang W, Bao Z, Jiang T.
Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Gliomas.
Genomics Proteomics Bioinformatics. 2021 Mar 2:S1672-0229(21)00045-0. doi: 10.1016/j.gpb.2020.10.005. Epub ahead of print. PMID: 33662628. Clinical tool.



High-grade gliomas



Cindil E, Sendur HN, Cerit MN, Erdogan N, Celebi F, Dag N, Celtikci E, Inan A, Oner Y, Tali T.
Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
Acad Radiol. 2021 Mar 5:S1076-6332(21)00064-7. doi: 10.1016/j.acra.2021.02.002. Epub ahead of print. PMID: 33685792. Retrospective analysis;




Mladenovsk M, Valkov I, Ovcharov M, Vasilev N, Duhlenski I.
High Grade Glioma Surgery - Clinical Aspects and Prognosis.
Folia Med (Plovdiv). 2021 Feb 28;63(1):35-41. doi: 10.3897/folmed.63.e55255. PMID: 33650394. Retrospective analysis.



Low-grade gliomas



Prabhu RS, Ward MC, Heinzerling JH, Corso CD, Buchwald ZS, Dhakal R, Asher AL, Sumrall AL, Burri SH.
The Association Between Radiation Therapy Dose and Overall Survival in Patients With Intracranial Infiltrative Low-Grade Glioma Treated With Concurrent and/or Adjuvant Chemotherapy.
Adv Radiat Oncol. 2021 Jan 1;6(1):100577. doi: 10.1016/j.adro.2020.09.017. Epub 2020 Oct 26. PMID: 33665485. Retrospective analysis.




Wang P, Luo C, Hong PJ, Rui WT, Wu S.
The Role of Surgery in IDH-Wild-Type Lower-Grade Gliomas: Threshold at a High Extent of Resection Should be Pursued.
Neurosurgery. 2021 Feb 27:nyab052. doi: 10.1093/neuros/nyab052. Epub ahead of print. PMID: 33647953. Retrospective analysis;



Diffuse astrocytic and oligodendroglial tumors



Glioblastoma



Brown PD, Chung C, Liu DD, McAvoy S, Grosshans D, Al Feghali K, Mahajan A, Li J, McGovern SL, McAleer MF, Ghia AJ, Sulman EP, Penas-Prado M, de Groot JF, Heimberger AB, Wang J, Armstrong TS, Gilbert MR, Guha-Thakurta N, Wefel JS.
A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma.
Neuro Oncol. 2021 Feb 27:noab040. doi: 10.1093/neuonc/noab040. Epub ahead of print. PMID: 33647972. Phase 2 trial; ⍈




Carles M, Popp I, Starke MM, Mix M, Urbach H, Schimek-Jasch T, Eckert F, Niyazi M, Baltas D, Grosu AL.
FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
Radiat Oncol. 2021 Mar 3;16(1):46. doi: 10.1186/s13014-020-01744-8. PMID: 33658069. Retrospective analysis.




Ferro M, Ferro M, Macchia G, Cilla S, Buwenge M, Re A, Romano C, Boccardi M, Picardi V, Cammelli S, Cucci E, Mignogna S, Di Lullo L, Valentini V, Morganti AG, Deodato F.
Post-Operative Accelerated-Hypofractionated Chemoradiation With Volumetric Modulated Arc Therapy and Simultaneous Integrated Boost in Glioblastoma: A Phase I Study (ISIDE-BT-2).
Front Oncol. 2021 Feb 22;10:626400. doi: 10.3389/fonc.2020.626400. PMID: 33692944. Phase 1 trial.




Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R, Lukas RV, Jovanovic B, McCortney K, Colman H, Chen S, Lai B, Antipova O, Deng J, Li L, Tommasini-Ghelfi S, Hurley LA, Unruh D, Sharma NV, Kandpal M, Kouri FM, Davuluri RV, Brat DJ, Muzzio M, Glass M, Vijayakumar V, Heidel J, Giles FJ, Adams AK, James CD, Woloschak GE, Horbinski C, Stegh AH.
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.
Sci Transl Med. 2021 Mar 10;13(584):eabb3945. doi: 10.1126/scitranslmed.abb3945. PMID: 33692132. Phase 0 trial;




Kurdi M, Butt NS, Baeesa S, Alghamdi B, Maghrabi Y, Bardeesi A, Saeedi R, Dallol A, Mohamed F, Bari MO, Samkari A, Lary AI, Alkhayyat S.
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies.
J Neurooncol. 2021 Mar 4. doi: 10.1007/s11060-021-03723-9. Epub ahead of print. PMID: 33661424. Retrospective analysis.




Lim J, Park Y, Ahn JW, Sim J, Kang SJ, Hwang S, Chun J, Choi H, Kim SH, Chun DH, Sung KS, Kwack K, Cho K.
Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial.
PLoS One. 2021 Mar 10;16(3):e0247293. doi: 10.1371/journal.pone.0247293. PMID: 33690665. Phase1-2 trial.




Priya S, Ward C, Locke T, Soni N, Maheshwarappa RP, Monga V, Agarwal A, Bathla G.
Glioblastoma and primary central nervous system lymphoma: differentiation using MRI derived first-order texture analysis - a machine learning study.
Neuroradiol J. 2021 Mar 3:1971400921998979. doi: 10.1177/1971400921998979. Epub ahead of print. PMID: 33657924. Retrospective analysis;



*

Skaga E, Skretteberg MA, Johannesen TB, Brandal P, Vik-Mo EO, Helseth E, Langmoen IA.
Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?
Neurooncol Adv. 2021 Feb 26;3(1):vdab008. doi: 10.1093/noajnl/vdab008. PMID: 33665615. Retrospective analysis.




Wong QH, Li KK, Wang WW, Malta TM, Noushmehr H, Grabovska Y, Jones C, Chan AK, Kwan JS, Huang QJ, Wong GC, Li WC, Liu XZ, Chen H, Chan DT, Mao Y, Zhang ZY, Shi ZF, Ng HK.
Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.
Mod Pathol. 2021 Mar 10. doi: 10.1038/s41379-021-00778-x. Epub ahead of print. PMID: 33692446. Laboratory investigation;




Yamaguchi S, Motegi H, Ishi Y, Okamoto M, Sawaya R, Kobayashi H, Terasaka S, Houkin K.
Clinical Outcome of Cytoreductive Surgery Prior to Bevacizumab for Patients with Recurrent Glioblastoma: A Single-center Retrospective Analysis.
Neurol Med Chir (Tokyo). 2021 Mar 4. doi: 10.2176/nmc.oa.2020-0308. Epub ahead of print. PMID: 33658457. Retrospective analysis.



Diffuse midline glioma



Li D, Bonner ER, Wierzbicki K, Panditharatna E, Huang T, Lulla R, Mueller S, Koschmann C, Nazarian J, Saratsis AM.
Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.
Sci Rep. 2021 Mar 3;11(1):5098. doi: 10.1038/s41598-021-84513-1. PMID: 33658570. Clinical tool.




Wang Y, Feng LL, Ji PG, Liu JH, Guo SC, Zhai YL, Sankey EW, Wang Y, Xue YR, Wang N, Lou M, Xu M, Chao M, Gao GD, Qu Y, Gong L, Wang L.
Clinical Features and Molecular Markers on Diffuse Midline Gliomas With H3K27M Mutations: A 43 Cases Retrospective Cohort Study.
Front Oncol. 2021 Feb 15;10:602553. doi: 10.3389/fonc.2020.602553. PMID: 33659209. Retrospective analysis.



Embryonal tumors



Medulloblastoma



Fan Q, Gong T, Zheng C, Ng JMY, Chen J, Myers C, Hensley H, Curran T, Yang ZJ.
Statins repress hedgehog signaling in medulloblastoma with no bone toxicities.
Oncogene. 2021 Mar;40(12):2258-2272. doi: 10.1038/s41388-021-01701-z. Epub 2021 Mar 1. PMID: 33649536. Laboratory investigation;




Naung H, Cohen KJ.
An intrathecal limited postoperative chemotherapy regimen for the treatment of young children with nodular/desmoplastic medulloblastoma and medulloblastoma with extensive nodularity.
J Neurooncol. 2021 Mar 10. doi: 10.1007/s11060-021-03727-5. Epub ahead of print. PMID: 33689104. Pilot study;



Meningiomas


Champeaux-Depond C, Weller J.
Tamoxifen. A treatment for meningioma?
Cancer Treat Res Commun. 2021 Feb 24;27:100343. doi: 10.1016/j.ctarc.2021.100343. Epub ahead of print. PMID: 33647870. Retrospective analysis.




Kieu DH, Trinh TH, Nguyen SL, Ngo HM.
Extracranial meningioma in the scalp skin 25 years after epidural hematoma surgery: A case report.
Int J Surg Case Rep. 2021 Mar 8;81:105734. doi: 10.1016/j.ijscr.2021.105734. Epub ahead of print. PMID: 33721823. Case report.



Mesenchimal non-meningothelial tumors



Hemangiopericytoma



Okubo T, Nagoshi N, Tsuji O, Tachibana A, Kono H, Suzuki S, Okada E, Fujita N, Yagi M, Matsumoto M, Nakamura M, Watanabe K.
Imaging Characteristics and Surgical Outcomes in Patients With Intraspinal Solitary Fibrous Tumor/Hemangiopericytoma: A Retrospective Cohort Study.
Global Spine J. 2021 Mar 11:2192568221994799
. doi: 10.1177/2192568221994799. Epub ahead of print. PMID: 33691508. Retrospective analysis.




Metastatic tumors


Moran R.
Transient visual disturbances as a primary manifestation of metastatic brain tumours.
Clin Exp Optom. 2021 Feb 22:1-2. doi: 10.1080/08164622.2021.1878830. Epub ahead of print. PMID: 33689615. Retrospective analysis,




Yao L, Feng M, Li XT, Gan WJ, Xu XT, Zhou YX.
Clinical study of salivary gland malignant tumor with skull base metastasis.
Br J Neurosurg. 2021 Feb 27:1-7. doi: 10.1080/02688697.2021.1885616. Epub ahead of print. PMID: 33641541. Retrospective analysis;





bottom

***********************